KR101320718B1 - 세균 감염 치료용 조합 약제 - Google Patents

세균 감염 치료용 조합 약제 Download PDF

Info

Publication number
KR101320718B1
KR101320718B1 KR1020097019585A KR20097019585A KR101320718B1 KR 101320718 B1 KR101320718 B1 KR 101320718B1 KR 1020097019585 A KR1020097019585 A KR 1020097019585A KR 20097019585 A KR20097019585 A KR 20097019585A KR 101320718 B1 KR101320718 B1 KR 101320718B1
Authority
KR
South Korea
Prior art keywords
pharmaceutically acceptable
acceptable salt
formula
antibiotic
carbapenem
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020097019585A
Other languages
English (en)
Korean (ko)
Other versions
KR20090122357A (ko
Inventor
에릭 드자브르
말콤 지.피. 페이지
Original Assignee
바실리어 파마슈티카 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바실리어 파마슈티카 아게 filed Critical 바실리어 파마슈티카 아게
Publication of KR20090122357A publication Critical patent/KR20090122357A/ko
Application granted granted Critical
Publication of KR101320718B1 publication Critical patent/KR101320718B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020097019585A 2007-03-23 2008-03-19 세균 감염 치료용 조합 약제 Expired - Fee Related KR101320718B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07006053.8 2007-03-23
EP07006053 2007-03-23
PCT/EP2008/053336 WO2008116813A2 (en) 2007-03-23 2008-03-19 Combination medicaments for treating bacterial infections

Publications (2)

Publication Number Publication Date
KR20090122357A KR20090122357A (ko) 2009-11-27
KR101320718B1 true KR101320718B1 (ko) 2013-10-21

Family

ID=38293982

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097019585A Expired - Fee Related KR101320718B1 (ko) 2007-03-23 2008-03-19 세균 감염 치료용 조합 약제

Country Status (13)

Country Link
US (2) US8486929B2 (https=)
EP (1) EP2124942B1 (https=)
JP (2) JP2010521517A (https=)
KR (1) KR101320718B1 (https=)
CN (1) CN101641095B (https=)
AU (1) AU2008231854B2 (https=)
BR (1) BRPI0809147A2 (https=)
CA (1) CA2680018C (https=)
MX (1) MX2009009918A (https=)
NZ (1) NZ579375A (https=)
RU (1) RU2488394C2 (https=)
WO (1) WO2008116813A2 (https=)
ZA (1) ZA200906349B (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2124942B1 (en) * 2007-03-23 2016-04-27 Basilea Pharmaceutica AG Combination medicaments for treating bacterial infections
KR20110095856A (ko) * 2008-12-01 2011-08-25 글레이드 올가닉스 프라이비트 리미티드 아즈트레오남과 카르바페넴류인 메로페넴 및 에르타페넴의 상승작용적 조합
AU2009329169B2 (en) 2008-12-19 2012-06-28 Pfizer Inc. Monocarbams
CA2807546C (en) 2010-08-10 2022-08-23 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
KR101315483B1 (ko) * 2011-06-23 2013-10-07 주식회사 아리바이오 항생제 및 라이소포스파티딜콜린을 포함하는 면역 증강 또는 세균성 감염 질환 치료용 조성물
WO2013033461A1 (en) 2011-08-31 2013-03-07 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
UY34585A (es) * 2012-01-24 2013-09-02 Aicuris Gmbh & Co Kg Compuestos b-lactámicos sustituidos con amidina, su preparación y uso
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
MX2015008627A (es) 2013-01-04 2015-09-23 Rempex Pharmaceuticals Inc Derivados de acido boronico y usos terapeuticos de los mismos.
KR20150103269A (ko) 2013-01-04 2015-09-09 렘펙스 파머수티클스 인코퍼레이티드 보론산 유도체 및 그의 치료적 용도
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
EP3139930B1 (en) 2014-05-05 2024-08-14 Melinta Therapeutics, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
ES2750805T3 (es) 2014-05-05 2020-03-27 Rempex Pharmaceuticals Inc Síntesis de sales de boronato y usos de las mismas
AU2015264418A1 (en) 2014-05-19 2016-11-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2016003929A1 (en) 2014-07-01 2016-01-07 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US10662205B2 (en) 2014-11-18 2020-05-26 Qpex Biopharma, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
RU2618433C2 (ru) * 2015-08-10 2017-05-03 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Санкт-Петербургский государственный университет" (СПбГУ) Антимикробная комбинация в отношении устойчивых к карбапенемам грамотрицательных бактерий вида pseudomonas aeruginosa, продуцирующих металло-β-лактамазу
MX389349B (es) 2016-06-30 2025-03-20 Qpex Biopharma Inc Derivados de ácido borónico y usos terapéuticos de los mismos.
CN107641119B (zh) * 2016-07-21 2019-11-08 中国科学院上海药物研究所 单环β-内酰胺-铁载体轭合物及其制备方法和用途
RU2666619C2 (ru) * 2016-12-01 2018-09-11 Федеральное государственное бюджетное образовательное учреждение высшего образования "Санкт-Петербургский государственный университет" (СПбГУ) АНТИМИКРОБНАЯ КОМБИНАЦИЯ В ОТНОШЕНИИ УСТОЙЧИВЫХ К КАРБАПЕНЕМАМ ГРАМОТРИЦАТЕЛЬНЫХ БАКТЕРИЙ ВИДА ACINETOBACTER BAUMANNII, ПРОДУЦИРУЮЩИХ МЕТАЛЛО-β-ЛАКТАМАЗУ
US20200093814A1 (en) 2016-12-21 2020-03-26 Aicuris Gmbh & Co. Kg Combination therapy with amidine substituted beta-lactam compounds and beta-lactamase inhibitors for infections with antibiotic resistant bacterial strains
US11286270B2 (en) 2017-10-11 2022-03-29 Qpex Biopharma, Inc. Boronic acid derivatives and synthesis thereof
EP3747883A4 (en) 2018-01-29 2020-12-16 Medshine Discovery Inc. MONOCYCLIC B-LACTAM COMPOUND FOR TREATING BACTERIAL INFECTION
EP3781576B1 (en) 2018-04-20 2024-06-12 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
EP3901150B1 (en) 2018-12-18 2025-12-03 Shenzhen Optimum Biological Technology Co., Ltd Monocyclic beta-lactam compound for use in the treatment of pneumonia
US20220133699A1 (en) 2019-02-14 2022-05-05 Singapore Eye Research Institute Antibacterial Compositions
US12491180B2 (en) 2019-12-19 2025-12-09 Shenzhen Optimum Biological Technology Co., Ltd Application of compound in treating pneumonia
AU2021266715A1 (en) 2020-05-05 2022-11-17 Qpex Biopharma, Inc. Boronic acid derivatives and synthesis, polymorphic forms, and therapeutic uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010020181A (ko) * 1997-04-24 2001-03-15 나에자 파마슈티칼 인코포레이티드 강력한 β-락타마아제 억제제인 2-옥소-1-아제티딘 술폰산
US20050065141A1 (en) * 2003-07-31 2005-03-24 Odink Debra A. Carbapenems useful in treating and preventing pulmonary infections, pharmaceutical compositions thereof and modes of administration thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1575803A (en) 1976-03-09 1980-10-01 Fujisawa Pharmaceutical Co 3,7 disubstituted 3 cephem 4 carboxylic acid compounds andprocesses for the preparation thereof
CA1283404C (en) 1986-07-01 1991-04-23 Shigeru Sanai Cephalosporin compounds, processes for their preparation and antibacterial agents
US5994340A (en) 1997-08-29 1999-11-30 Synphar Laboratories, Inc. Azetidinone derivatives as β-lactamase inhibitors
US6916803B2 (en) * 2000-09-14 2005-07-12 Pantherix, Ltd. 3-(Heteroaryl acetamido)-2-oxo-azetidine-1-sulfonic acids derivatives as antibacterial agents
WO2007065288A2 (en) * 2005-12-07 2007-06-14 Basilea Pharmaceutica Ag Useful combinations of monobactam antibiotics with beta-lactamase inhibitors
EP2124942B1 (en) * 2007-03-23 2016-04-27 Basilea Pharmaceutica AG Combination medicaments for treating bacterial infections

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010020181A (ko) * 1997-04-24 2001-03-15 나에자 파마슈티칼 인코포레이티드 강력한 β-락타마아제 억제제인 2-옥소-1-아제티딘 술폰산
US20050065141A1 (en) * 2003-07-31 2005-03-24 Odink Debra A. Carbapenems useful in treating and preventing pulmonary infections, pharmaceutical compositions thereof and modes of administration thereof

Also Published As

Publication number Publication date
JP2010521517A (ja) 2010-06-24
CA2680018A1 (en) 2008-10-02
MX2009009918A (es) 2009-10-19
BRPI0809147A2 (pt) 2014-08-26
CA2680018C (en) 2014-01-07
AU2008231854A1 (en) 2008-10-02
US20130274238A1 (en) 2013-10-17
US8486929B2 (en) 2013-07-16
EP2124942B1 (en) 2016-04-27
WO2008116813A2 (en) 2008-10-02
NZ579375A (en) 2012-02-24
ZA200906349B (en) 2010-06-30
CN101641095B (zh) 2012-10-31
US20100144699A1 (en) 2010-06-10
AU2008231854B2 (en) 2013-03-21
JP2013253094A (ja) 2013-12-19
US8809315B2 (en) 2014-08-19
JP5779209B2 (ja) 2015-09-16
RU2009139004A (ru) 2011-04-27
EP2124942A2 (en) 2009-12-02
WO2008116813A9 (en) 2008-11-27
HK1138184A1 (en) 2010-08-20
RU2488394C2 (ru) 2013-07-27
CN101641095A (zh) 2010-02-03
KR20090122357A (ko) 2009-11-27
WO2008116813A3 (en) 2009-01-22

Similar Documents

Publication Publication Date Title
KR101320718B1 (ko) 세균 감염 치료용 조합 약제
EP2484680B1 (en) Useful Combinations of Monobactam Antibiotics with beta-Lac-tamase Inhibitors
AU2002212614B2 (en) 3-(heteroaryl acetamido)-2-oxo-azetidine-1-sulfonic acids derivatives as antibacterial agents
RU2675847C2 (ru) Комбинированные терапевтические средства, содержащие оксазолидинон-хинолоны, предназначенные для лечения бактериальных инфекций
BR112013028813B1 (pt) derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e composições farmacêuticas que os compreendem
CN104768951A (zh) 1,6-二氮杂双环[3,2,1]辛-7-酮衍生物及其在治疗细菌感染中的用途
US20130244929A1 (en) Bridged lipoglycopeptides that potentiate the activity of beta-lactam antibacterials
TW474935B (en) Cephalosporin antibiotics
CN106211771A (zh) 含氮化合物及其作为抗菌剂的用途
KR20140052927A (ko) 화합물 및 그의 용도
RU2281948C2 (ru) Цефалоспориновые антибиотики, фармацевтическая композиция на их основе и способ лечения инфекции
JP5276653B2 (ja) カルバペネム類を含む殺菌性抗ｍｒｓａ活性医薬組成物
HK1138184B (en) Combination medicaments for treating bacterial infections
RU2172317C2 (ru) Производные цефалоспорина, содержащая их антибактериальная композиция, производные 2-аминотиазолов в качестве промежуточных соединений и способ их получения
JP2005509039A (ja) Ｃ−３がｓ／ｏおよびｓ／ｎである新規なセファロスポリンのホルムアルデヒドアセタール誘導体およびその抗生物質としての使用

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20161016

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20161016

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000